Form 8-K - Current report:
SEC Accession No. 0001193125-24-200684
Filing Date
2024-08-14
Accepted
2024-08-14 16:43:00
Documents
16
Period of Report
2024-08-13
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d874118d8k.htm   iXBRL 8-K 27805
2 EX-1.1 d874118dex11.htm EX-1.1 229559
3 EX-5.1 d874118dex51.htm EX-5.1 11796
7 GRAPHIC g874118dsp001.jpg GRAPHIC 6090
  Complete submission text file 0001193125-24-200684.txt   469580

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA anab-20240813.xsd EX-101.SCH 2860
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE anab-20240813_lab.xml EX-101.LAB 17995
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE anab-20240813_pre.xml EX-101.PRE 11268
19 EXTRACTED XBRL INSTANCE DOCUMENT d874118d8k_htm.xml XML 3670
Mailing Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121
Business Address 10770 WATERIDGE CIRCLE, SUITE 210 SAN DIEGO CA 92121 858-362-6295
ANAPTYSBIO, INC (Filer) CIK: 0001370053 (see all company filings)

EIN.: 203828755 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37985 | Film No.: 241208951
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)